Symbiotec Pharmalab Ltd (SYMBIOTEC) is currently trading at 1,243.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Symbiotec Pharmalab Limited is an industrial‑scale, research‑driven pharmaceutical and biotechnology platform focused on steroidal hormone and corticosteroid APIs, with new forward‑integrated verticals in biotech CDMO services and complex injectables built on decades of regulatory approvals and backward integration. The company reported Q1 FY27 consolidated revenue of INR218 crores (API INR215 crores) with API gross margins above 60% and API EBITDA of INR66 crores; consolidated EBITDA was INR45 crores and net profit INR14 crores while new verticals currently create an operating expense and depreciation drag on consolidated profits. Management has deployed roughly INR1,000 crores into two new facilities (400 kL fermentation at Ujjain and a complex injectables plant at Mhow), stated that a large part of existing fermentation capacity is already contracted under take‑or‑pay terms, and plans a 600 kL Phase‑1 expansion funded by internal accruals and partner capital. Symbiotec’s strategic differentiators include full backward integration from phytosterols to finished APIs, substantial regulatory trust with US FDA, EU GMP and other approvals, a broad DMF/CEP filing footprint and long‑duration customer relationships that create stickiness and predictable base revenues. Near‑term catalysts are revenue recognition from milestone payments and initial CDMO revenues expected in H2 FY27–FY28, regulatory outcomes from a recent FDA audit at Pithampur, and potential rapid commercial scale‑up if take‑or‑pay arrangements convert into sustained throughput and additional brownfield expansions.

Over the past 52 weeks, Symbiotec Pharmalab Ltd has traded between a low of ₹933.80 and a high of ₹1,310.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Symbiotec Pharmalab Ltd has a market capitalization of approximately 8,046.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Symbiotec Pharmalab Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 69.76 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 8,046.47 Cr, Symbiotec Pharmalab Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Symbiotec Pharmalab Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Symbiotec Pharmalab Ltd is 69.76. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

VAI stands for Voluntary Action Indicated. It means observations were noted, but the FDA does not require enforcement action, and the company is expected to address issues voluntarily.

The earnings conference call is scheduled for September 22, 2026 at 10:00 AM IST.